Resources

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.

Intelligent upgrade of existing, purpose-built laboratory spaces will be available for occupation from Q3, 2025.

In this article, Giuseppe Amoroso, R&D Tax Advisor for biotech companies, explores the critical role of R&D tax compliance in the biotechnology sector.

The UK’s biotech sector continues to break new ground, from sustainable medicine manufacturing to AI-driven healthcare advancements. This week, I analyse key developments shaping the industry, including the launch of the Sustainable Medicine Manufacturing Innovation Programme, the BIA’s role in the government’s Spending Review, and the UK’s leadership in cultivated meat.

This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix’s AI-powered software to expand access to life-changing stroke treatments across networks.

In this article, Dr. Fawzi Abou-Chahine, Grants Director at FI Group UK, delves into the evolving landscape of grant funding in the biotechnology sector.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at JP Morgan Healthcare Week. 

United Kingdom National Nuclear Laboratory and Medicines Discovery Catapult have received funding to drive the development of innovative approaches for new cancer treatments.

It has been hugely exciting to partner with the BIA and its members as their charity of the year throughout 2024. We want to extend a heartfelt thank you to the BIA and all its member organisations for their incredible support, enthusiasm, and generosity.

Relation Therapeutics announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.

A new total-body PET scanner that is quicker for the patient and produces higher quality images for faster and earlier diagnosis and treatment of illnesses like cancer and heart conditions, was unveiled by Ministers in London yesterday (Wednesday 27 November).

A new independent report evaluating the economic and scientific impact of the Babraham Research Campus has revealed significant contributions not only to the UK and global life sciences sector, but to the local Cambridge and wider UK economy.

London was the epicentre of the life science industry during London Life Sciences Week last week. The 2024 edition marked a significant step forward in both the quality and quantity of events and interactions.

Quell Therapeutics CEO, Iain McGill and the team welcomed Rt Hon Rachel Reeves, Chancellor of the Exchequer, to the Translation & Innovation Hub in London to officially open their newly refurbished offices.

Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae; PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects

Further strengthens Poolbeg's robust intellectual property portfolio

Quotient Sciences announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), a modular, integrated, and automated RNA-micro factory which enables the end-to-end production of various RNA-based products.